Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2021

View Archived Issues

British Pakistani genomics study illustrates need for diversity

Engineered AAV capsids allow specific transgene expression in the brain of mouse and marmoset

Alphataxin increases CD4+ tumor-infiltrating T cells and suppresses renal cell cancer in mice

Dual PI3K/BRD4 inhibitors divulged by Monash University, Peter MacCallum Cancer Centre

CSIPI and Shanghai Zhongze Therapeutics patent dopamine D2/D3/5-HT2A receptor antagonists

Trinuero, DGMIF identify SERT, NET and DAT inhibitors

Janssen Pharmaceutica synthesizes new Mcl-1 inhibitors

New USP30 inhibitors identified at Mission Therapeutics

Anti-CD47 antibody ADG-153 shows promising preclinical data for cancer immunotherapy

Gene expression of extramedullary multiple myeloma samples points to new targets

Evusheld retains neutralizing activity against Omicron variant

WestVac BioPharma's COVID-19 vaccine shows high titer neutralizing antibodies against Omicron

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...